We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Protagen to Apply UNIarray® Platform for Biogen Idec
Product News

Protagen to Apply UNIarray® Platform for Biogen Idec

Protagen to Apply UNIarray® Platform for Biogen Idec
Product News

Protagen to Apply UNIarray® Platform for Biogen Idec


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Protagen to Apply UNIarray® Platform for Biogen Idec"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Protagen AG, has announced that they will be using the UNIarray® Platform to help discover biomarkers in relapsing remitting multiple sclerosis for Biogen Idec, Inc. Under the terms of the agreement, Protagen will apply it’s UNIarray® technology platform and expertise in autoantibody research to support retrospective analysis of samples from a Biogen Idec clinical trial for the purpose of finding predictive and response biomarkers associated with multiple sclerosis (MS) therapy.

“There is an acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic level markers,” said Dr. Peter Schulz-Knappe, CSO of Protagen AG. “Autoantibody signatures play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression.”

“Pharmaceutical companies recognize more and more the importance of autoantibody signatures for drug development, and Protagen provides the right technology and unique expertise for collaborations in this area”, said Dr. Stefan Müllner, CEO.

UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer and neurodegenerative disorders.

The systematic and indication-specific determination of autoantibody patterns will serve as a powerful basis to address hitherto unmet diagnostic needs. UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.

Advertisement